HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Susan L Ford Selected Research

cabotegravir

11/2021Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
11/2021Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
1/2021Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
1/2020Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
1/2019Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir.
1/2019A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls.
1/2018Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
9/2017Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
1/2017Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
1/2016Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Susan L Ford Research Topics

Disease

12Infections
11/2021 - 04/2007
5Injection Site Reaction
11/2021 - 12/2014
4Pain (Aches)
01/2020 - 01/2017
4HIV Infections (HIV Infection)
01/2019 - 11/2013
2Diarrhea
01/2014 - 01/2014
2Headache (Headaches)
04/2007 - 06/2006
1Dizziness (Lightheadedness)
12/2014
1Hypersensitivity (Allergy)
01/2014
1Cough
01/2014
1Gastroenteritis
01/2014
1Otitis Media
01/2014
1Respiratory Tract Infections (Respiratory Tract Infection)
01/2014
1Vomiting
01/2014
1Bartonella Infections (Bartonellosis)
10/2008
1Tuberculosis (Tuberculoses)
02/2008

Drug/Important Bio-Agent (IBA)

12cabotegravirIBA
11/2021 - 07/2015
7Rilpivirine (TMC-278)IBA
11/2021 - 11/2013
4Pharmaceutical PreparationsIBA
10/2015 - 06/2006
2Integrase InhibitorsIBA
01/2019 - 01/2019
2TabletsIBA
01/2019 - 01/2016
2Reverse Transcriptase InhibitorsIBA
10/2015 - 11/2013
1lamivudine drug combination abacavirFDA Link
01/2020
1dolutegravirIBA
01/2020
1Human immunodeficiency virus 1 p31 integrase proteinIBA
01/2017
1Antiviral Agents (Antivirals)IBA
01/2017
1HIV IntegraseIBA
01/2016
1NucleosidesIBA
10/2015
1abacavir (Ziagen)FDA Link
01/2014
1RNA (Ribonucleic Acid)IBA
01/2014
1isinglassIBA
10/2008
1Rifabutin (Ansamycin)FDA Link
02/2008
1brecanavirIBA
04/2007
1Protease Inhibitors (Protease Inhibitor)IBA
04/2007

Therapy/Procedure

8Injections
11/2021 - 12/2014
3Therapeutics
01/2020 - 12/2014